Trial Profile

Multicenter, Phase IV, Open-Label, Uncontrolled Study to Assess the Efficacy and Safety of a Single Intravenous Dose of Palonosetron 0.25 mg (Aloxi, Onicit, Paloxi) in the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Non-Hodgkin s Lymphomas Undergoing Repeated Cycles of Moderately Emetogenic Chemotherapy.

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 10 Nov 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

24 Mar 2012 Actual end date (Apr 2011) added as reported by European Clinical Trials Database record.
24 Mar 2012 Status changed from recruiting to discontinued as reported by European Clinical Trials Database record.
06 Aug 2011 This trial is recruiting in Czech Republic, Germany and has completed in Italy.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com